Literature Lessons
A single center retrospective analysis compared 7,361 biological drug recipients with 74,910 matched patients. There was not an increased risk of COVID-19 infection or an increased risk of COVID-19-related mortality among the biologic drug recipient cohort. Prominent among the drugs received were adalimumab (28.4%), infliximab (15.6%), and etanercept (11.9%), as well as rituximab (15.6%) and […]